Finland
Diabetes country report 2000 — 2050
Number of adults (20–79 years) with diabetes in Finland (FI)
2000 | 158.7 thousand |
2011 | 340.3 thousand |
2024 | 400.4 thousand |
2050 | 389.8 thousand |
Finland is one of the 60 countries and territories in the IDF Europe Region.
Data source(s) used for the diabetes estimates in adults:
- Saaristo TE et al. BMC Public Health. 2008 Dec 29;8:423. PMID:19113993.
- Finnish Institute for Health and Welfare. National Health Survey 2017.
Diabetes estimates (20-79 y) | ||||
---|---|---|---|---|
People with diabetes, in 1,000s | 158.7 | 340.3 | 400.4 | 389.8 |
Age-standardised prevalence of diabetes, % | - | 5.8 | 6.9 | 8.2 |
Proportion of people with undiagnosed diabetes, % | - | - | 18.8 | - |
People with undiagnosed diabetes, in 1,000s | - | - | 75.1 | - |
Impaired Fasting Glucose (IFG) | ||||
---|---|---|---|---|
People with IFG, in 1,000s | - | - | 198.5 | 197.5 |
Age-standardised prevalence of IFG, % | - | - | 4.6 | 4.8 |
Impaired Glucose Tolerance (IGT) | ||||
---|---|---|---|---|
People with IGT, in 1,000s | - | 381.7 | 439.2 | 427.2 |
Age-standardised prevalence of IGT, % | - | 6.7 | 7.9 | 9.2 |
Mortality attributable to diabetes (20-79 y) | ||||
---|---|---|---|---|
Deaths attributable to diabetes | - | 2,753.0 | 4,042.1 | - |
Proportion of diabetes-related deaths in people 20-79 y, % | - | - | 15.7 | - |
Hyperglycaemia in pregnancy (HIP) (20-49 y) | ||||
---|---|---|---|---|
Live births affected by HIP | - | - | 5,391.4 | - |
Prevalence of gestational diabetes mellitus (GDM), % | - | - | 12.0 | - |
Live births affected by other types of diabetes first detected in pregnancy | - | - | 38.7 | - |
Live births affected by other types of diabetes detected prior to pregnancy | - | - | 167.8 | - |
Diabetes-related health expenditure | ||||
---|---|---|---|---|
Total diabetes-related health expenditure, USD million | - | - | 2,049.1 | 1,824.8 |
Total diabetes-related health expenditure, ID million | - | - | 2,022.5 | 1,801.2 |
Diabetes-related health expenditure per person, USD | - | 4,976.0 | 5,118.0 | 4,681.6 |
Diabetes-related health expenditure per person, ID | - | - | 5,051.7 | 4,620.9 |
Type 1 diabetes estimates in children and adolescents | ||||
---|---|---|---|---|
People with type 1 diabetes (all age groups) | - | - | 54,307.0 | - |
People with type 1 diabetes (0-19 y) | - | - | 7,654.3 | - |
Demographics | ||||
---|---|---|---|---|
Total adult population (20-79 y), in 1,000s | 3,731.0 | 3,907.8 | 4,082.1 | 3,878.4 |
Population of children and adolescents (0-19 y) | - | - | 1,138,769.0 | - |
Diabetes estimates (20-79 y) | |
---|---|
People with diabetes, in 1,000s | 158.7 |
Age-standardised prevalence of diabetes, % | - |
Proportion of people with undiagnosed diabetes, % | - |
People with undiagnosed diabetes, in 1,000s | - |
Impaired Fasting Glucose (IFG) | |
---|---|
People with IFG, in 1,000s | - |
Age-standardised prevalence of IFG, % | - |
Impaired Glucose Tolerance (IGT) | |
---|---|
People with IGT, in 1,000s | - |
Age-standardised prevalence of IGT, % | - |
Mortality attributable to diabetes (20-79 y) | |
---|---|
Deaths attributable to diabetes | - |
Proportion of diabetes-related deaths in people 20-79 y, % | - |
Hyperglycaemia in pregnancy (HIP) (20-49 y) | |
---|---|
Live births affected by HIP | - |
Prevalence of gestational diabetes mellitus (GDM), % | - |
Live births affected by other types of diabetes first detected in pregnancy | - |
Live births affected by other types of diabetes detected prior to pregnancy | - |
Diabetes-related health expenditure | |
---|---|
Total diabetes-related health expenditure, USD million | - |
Total diabetes-related health expenditure, ID million | - |
Diabetes-related health expenditure per person, USD | - |
Diabetes-related health expenditure per person, ID | - |
Type 1 diabetes estimates in children and adolescents | |
---|---|
People with type 1 diabetes (all age groups) | - |
People with type 1 diabetes (0-19 y) | - |
Demographics | |
---|---|
Total adult population (20-79 y), in 1,000s | 3,731.0 |
Population of children and adolescents (0-19 y) | - |